Get started

UNH

United Health - Another decent bullrun of +50%!🚨United Health ( NYSE:UNH ) just continues its strong bullrun: 🔎Analysis summary: Just a couple of months ago, United Health retested a major confluence of support. Thus the recent rally of about +70% was actually also totally expected. Looking at the higher timeframe, United Health remains clearly bullish, heading for another +50% move soon. 📝Levels to watch: $475 and $650 Keep your #LONGTERMVISION🙏 — Phil (@TheTraderPhil)
NYSE:UNHLong
by TheTraderPhil
5
UNH Long — $UNH breaking out above the 405-410 consolidation sheHTF (4h): UNH bottomed near 260 in mid-March, reversed hard through April and May, establishing a clear sequence of HHs and HLs. The stock broke above the prior swing high near 400-405 on large volume (June 4 gap up on BofA upgrade catalyst) and has consolidated just above that broken resistance zone in the 400-410 range for ~two weeks — classic breakout-retest structure. Price is now pushing higher off that consolidation shelf with today's session printing new multi-week highs near 412-413. LTF (1h): After the June 4-8 rally to ~408-409, price pulled back and consolidated in a tight band (405-409 range through June 9-12). Today (June 15) opened with a gap down to 400 (testing the prior breakout zone), immediately reversed with a strong bounce, and current bars show progressive HHs: 408.9 → 411.7 → 413.1, closing at 412.2 — a clear micro-BOS through the June 12 high (~409). This is a pullback-to-breakout-level retest that triggered with intraday momentum. Entry at ask 412.22. Stop below today's intraday low (399.65) plus buffer; however, the honest invalidation for the breakout thesis is a close back below the consolidation shelf ~406.5 (0.5 ATR below the June 9-12 range floor ~407.4, i.e. 407.4 − 0.5×3.25 ≈ 405.8 → use 406.50 as the round stop). That gives stop distance of ~5.72. Target: first meaningful supply is the June 10 intraday high at ~416 and the prior swing cluster near 415-417; placing target at 424 (next structural area visible on the 4h chart, slightly in front of that supply zone). R/R = (424−412.22)/(412.22−406.50) = 11.78/5.72 = 2.06 — passes the gate cleanly. Research: BofA upgrade to Buy/$450 (T2), Morgan Stanley top pick/$453 (T2), Mizuho $460 (T2), and the Q1 beat with raised guidance (T1) all align strongly with the LONG thesis. Regulatory MA headwind is a modest offset. Earnings not until Aug 4, outside swing horizon. Market regime long_lean +5, scan hint Breakout/LONG +4. base 67; research +8 (T1+multiple T2 aligned); scan +4; regime +5 → 84, clamped 84. 📍 Entry: 412.22 🛑 Stop: 406.50 🎯 Target: 424.00 ⚖️ R:R: 2.06
NYSE:UNHLong
by mnktrd
United Health - This chart is just printing!👑United Health ( NYSE:UNH ) is respecting all analysis: 🔎Analysis summary: A couple of weeks ago, United Health actually retested a crazy long term confluence of support. And with this retest, a bullish rejection was actually more than expected. So far, United Health is nicely playing out and it is never a bad idea to start taking partial profits. 📝Levels to watch: $400 and $280 🙏🏻Keep your #LONGTERMVISION – Phil
NYSE:UNHLong
by TheTraderPhil
12
$UNH | Bull Flag Breakout with Multi-Timeframe Target ConfluenceUnitedHealth Group is breaking out of one of the cleanest bull flag setups I've tracked this quarter, with technical targets that align remarkably with longer-term structural levels. The Setup.UNH crashed roughly 61% from its April 2025 peak near $610 to an August 2025 low of $235, The stock then formed an 8-month diamond bottom consolidation pattern from August 2025 through March 2026, with a higher low retest at $253 in March 2026 confirming the structural floor. The Q1 2026 print on April 21 was the inflection point. Adjusted EPS of $7.23 beat estimates of $6.65, revenue came in at $111.7B, and full-year guidance was raised from $17.75 to $18.25 minimum. Stephen Hemsley, returning as CEO, is rebuilding operational discipline. Goldman Sachs added UNH to its Conviction Buy list on May 1, Evercore ISI raised its target to $400 (Outperform), and CMS finalized a 2.48% rate increase for 2027 Medicare Advantage plans, far above the near-flat proposal that originally crushed the stock in January. Technical Structure. Flagpole: March 2026 low ($253) to mid-May 2026 high ($395), a $142 / 56% move in 6 weeks Flag formation: descending parallel channel, 2 weeks duration, declining volume Breakout: Yesteday, +5.24% on 5.52M volume, daily close at $396.74 ADX(14): 37.99, confirming strong trend strength. Pierce of psychological $400 level intraday (high $401.38) Measured Move + Long-Term Target Confluence This is the part that makes this setup unusual. Bull flag measured move (flagpole projected from breakout point): $537 theoretical maximum, with $480-510 as the realistic 60-80% completion zone. Back in late May, I published a longer-term structural analysis of UNH identifying the multi-month diamond bottom formation with horizontal resistance targets at $416.28, $462.02, $512.52, $548.47, and $594.21. The full analysis with the diamond breakout structure is the link. $416 aligns with the first flag projection $462 sits inside the lower measured move range $512 sits inside the realistic completion zone $548 sits between realistic and maximum projection $594 maps almost exactly to the theoretical max When two independent technical methods, derived weeks apart, point to the same price regions, the probability skew toward upside expands meaningfully. This is not a single-pattern thesis. The diamond bottom from May projected these levels before the flag even formed. UNH is a genuine turnaround story emerging from a historic 61% drawdown with operational metrics improving and institutional sponsorship rebuilding. The technical structure is exceptionally clean, and the convergence between the diamond bottom targets from late May and the current flag measured move offers a rare risk/reward profile across multiple timeframes. Manage actively, take staged profits, and respect the regulatory tail risk. Not financial advice. Just sharing the setup as I see it.
NYSE:UNHLong
by Nati-EL
UnitedHealth Slips After Berkshire Hathaway Exits Stake!Shares of UnitedHealth Group came under renewed pressure after Berkshire Hathaway revealed that it had fully exited its position in the healthcare giant, a move that quickly captured investor attention across the market. Following the disclosure, UnitedHealth shares dropped sharply in premarket trading, falling by as much as 5.3% as traders reacted to the news and reassessed sentiment surrounding the company. The filing was particularly notable because Berkshire Hathaway, led by legendary investor Warren Buffett, had only rebuilt its stake in UnitedHealth within the past year. That earlier investment had been viewed by many market participants as a strong vote of confidence in the company’s long-term fundamentals and its dominant position within the U.S. healthcare industry. As a result, Berkshire’s decision to now completely exit the position has fueled speculation about whether the conglomerate sees increased risks ahead for the sector or believes better opportunities exist elsewhere. The selloff also arrives at a challenging time for the broader health insurance industry. Investors have become increasingly cautious as healthcare providers and insurers continue grappling with rising medical costs, reimbursement pressure, regulatory uncertainty, and shifting government policy. Concerns about higher healthcare utilization and growing expenses have weighed heavily on sentiment across the managed care space, leading analysts to closely monitor how insurers are managing profitability and forecasting future earnings growth. UnitedHealth, widely regarded as one of the largest and most influential healthcare companies in the United States, has not been immune to those concerns. In recent months, the company has faced mounting scrutiny over its margins, cost trends, and ability to maintain the strong earnings performance investors had previously come to expect. Market participants are also evaluating whether the company can continue balancing growth with profitability in an environment where healthcare spending pressures remain elevated. The reaction to Berkshire’s exit highlights how closely investors follow moves made by major institutional firms, especially when those firms are associated with long-term, value-oriented investing strategies. While Berkshire Hathaway’s sale does not necessarily signal a negative long-term outlook for UnitedHealth, the timing of the decision has nevertheless intensified debate about the near-term outlook for the healthcare insurance sector and whether additional volatility could lie ahead for the stock.
NYSE:UNHShort
by KalaGhazi
1
UNH UnitedHealth Group Incorporated Options Ahead of EarningsIf you haven`t sold UNH near the top: Now analyzing the options chain and the chart patterns of UNH UnitedHealth Group Incorporated prior to the earnings report this week, I would consider purchasing the 350usd strike price at the money Calls with an expiration date of 2026-12-18, for a premium of approximately $23.70. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:UNHLong
by TopgOptions
UNH: Massive Bear-Flag-Formation, Bearish-Wave Setup!Hello There, welcome to my new analysis about UNH on the weekly timeframe perspective. In recent times the stock crashed massively towards the downside. More than $300 billion of market cap has been evaporated, which resulted in massive selling pressure and heavy bearish volume. In such cases the possibility is enormously high that such a bearish downside pressure will not just reverse and turn bearish again. When looking at my chart, we can watch there how UNH is trading within this crucial descending channel formation. Within this formation, the upper boundary serves as a massive resistance. From there on, UNH already set up the -62% bearish dump towards the downside. Right now, the price of UNH is already approaching this upper boundary again. There is a high chance that it remains resistance, and UNH pulls back from there on. What is more important within this whole dynamic is the pivotal bear flag formation UNH is forming. This is a major bearish continuation formation. It will continue in the bearish direction once it has been completed, and it usually does not invalidate into the other direction. Right now, UNH is already completing the wave count within this whole formation. After this wave count, the whole formation will complete with a breakdown below the lower boundary. UNH also has several other resistances within this whole structure. As marked in my chart, UNH has a crucial resistance cluster consisting of the horizontal resistance, the resistance determined by the 500-MA marked in red, and the resistance of the upper boundary. Once UNH pulls back from this resistance, moves towards the downside, and completes the bear flag, it will activate the bearish target zones as marked in my chart. In this manner, thank you a lot for watching! I highly appreciate the support. VP
NYSE:UNH
by VincePrince
5
UNH 4H – Key Levels + Trade Scenarios (Breakout vs Pullback SUThesis: UnitedHealth (UNH) is approaching a key resistance level around 370, with clear structure forming on the 4H chart. Price is currently respecting well-defined support and resistance zones, giving us multiple high-probability scenarios. 🔴 Key Levels Resistance: 370 Active Support: 340–350 Lower Support: 310 Macro Support: 278 🎯 Trade Scenarios 1. Breakout (Bullish) If price breaks and holds above 370 Target: 385 → 400 Invalidation: Below 365 2. Rejection (Bearish Bias) If price rejects 370 Target: 350 → 340 Invalidation: Strong close above resistance 3. Pullback Buy (Best Setup) Entry: 340–350 zone Target: 370 Stop Loss: ~330 👉 Cleanest risk-to-reward setup if support holds. ⚖️ Risk Management Focus on RRR ≥ 1:1.5 Wait for confirmation (don’t chase price) Trade the reaction, not the prediction 🧠 Final Thoughts Market is at a decision point. Patience here matters more than execution speed. Amateurs chase price — professionals wait at levels.
NYSE:UNH
by SaeedAlexander
United Health - The next parabolic bullrun!🏅United Health ( NYSE:UNH ) formed a major bottom: 🔎Analysis summary: United Health has been correcting over -60% during 2025. But looking at the higher timeframe, the underlying trend remains incredibly bullish. United Health is retesting major support and actually setting up for a parabolic bullrun going into the rest of 2026. 📝Levels to watch: $300 SwingTraderPhil SwingTrading.Simplified. | Investing.Simplified. | #LONGTERMVISION
NYSE:UNHLong
by TheTraderPhil
12
UnitedHealth Gaps 8% on Q1 Beat — Analysts See $430.UnitedHealth Group just printed its strongest quarterly beat in two years. Q1 2026 EPS came in at $7.23 — beating Wall Street's $6.65 estimate by 9%. The company also raised its full-year profit outlook to more than $18.25 per share (up from $17.75). Revenue hit $111.72 billion. The stock gapped 8.88% at the open, reclaiming its year-to-date breakeven in a single session. This is not just a beat — it is a structural reset. Macro Context The key driver behind the beat: UNH's medical benefit ratio came in at 83.9%, far better than the 85.5% analysts expected. That means UnitedHealth is collecting more in premiums than it is paying out in claims — a margin story, not just a revenue story. On top of that, CMS finalized a 2.48% average payment rate increase for 2027 Medicare Advantage (versus the nearly flat 0.09% proposal that had scared the sector all year). That regulatory tailwind alone is worth multiple turns of multiple expansion. Three analysts raised price targets today: Morgan Stanley named UNH a Top Pick at $375. Jefferies raised to $373. Piper Sandler hiked to $430. Technical Analysis UNH has spent 6 months in a painful drawdown from its $510 ATH (Aug 2024) all the way to $245 in March 2026 — a 52% peak-to-trough decline that priced in a worst-case regulatory and medical cost scenario. Today's earnings print confirms the worst-case did not happen. The gap-up from $324 to $352 breaks above the January 2026 consolidation zone at $340-$355, which is now the entry zone. The 200-day SMA is declining near $370 — reclaiming it would be the next major technical confirmation signal. RSI on the daily has reset from 28 (oversold) to 62 — plenty of room before overbought. Key levels: Stop: $316 — below the gap-open support and the pre-earnings close. If price fills the gap completely, the thesis is wrong. Entry zone: $340–$355 — current trading range, gap consolidation base. TP1: $375 — Morgan Stanley and Jefferies consensus target, 200-day SMA reclaim. TP2: $400 — round number, pre-correction resistance level. TP3: $430 — Piper Sandler bull-case target, measured recovery from the 2026 lows. Trade Plan Direction: Long Entry: $340–$355 Stop: $316 Target 1: $375 (R:R 1:1.4) Target 2: $400 (R:R 1:2.2) Target 3: $430 (R:R 1:3.3) Timeframe: 4–10 weeks Risk / Invalidation Thesis breaks if UNH fills the earnings gap back below $320 on a daily close — that signals institutions are selling into the strength and the beat was already priced in. Also watch for any CMS policy reversal or surprise medical cost spike in the coming weeks. Educational Takeaway Earnings gap-ups on high-quality defensive names like UNH are among the most reliable post-event setups in the market. The key distinction: was the gap on BEAT + RAISE + CATALYST SHIFT? If yes, the gap is a new base, not a fade target. UNH today checks all three boxes — beat, raised guidance, AND a regulatory tailwind that changes the multi-year earnings trajectory. That combination makes this a buy-the-gap, not sell-the-gap setup.
NYSE:UNHLong
by PickMyTrade_Official
UNH (UnitedHealth Group) — Q1 Earnings Beat + Guidance Raise**💡 UNH (UnitedHealth Group) — Q1 Earnings Beat + Guidance Raise: Healthcare Bellwether Signals Strong Rebound** **SECTION 1 — Executive Summary** 💼 UnitedHealth Group delivered a decisive Q1 2026 earnings beat with adjusted EPS of $7.23 (versus ~$6.57 consensus) and revenue of $111.7 billion (+2% YoY), while raising full-year 2026 adjusted EPS guidance to >$18.25 amid disciplined pricing, cost controls, and Optum optimization. This mega-cap healthcare leader offers compelling value as it navigates medical cost pressures and regulatory scrutiny with a clear path to margin recovery and diversified growth. Overall rating: Buy. 12-month price target: $360 (blended DCF/comps methodology using normalized medical loss ratios and Optum contribution). The single biggest reason to own this stock right now is UnitedHealth’s unmatched scale across insurance and services (Optum), positioning it to capture long-term healthcare spending tailwinds while executing a proven turnaround plan. The single biggest risk remains elevated medical costs and Medicare Advantage reimbursement dynamics. **SECTION 2 — Business Overview** 🏢 UnitedHealth Group is the largest healthcare company in the United States, operating through two primary platforms: UnitedHealthcare (insurance and benefits) and Optum (health services, pharmacy care, and technology). Revenue breakdown (FY 2025): UnitedHealthcare ~77% (insurance premiums and fees), Optum ~23% but with higher margins and faster growth in value-based care, PBM, and data/analytics (sourced from company FY 2025 results released Jan 27 2026). Business model generates revenue primarily from health insurance premiums, service fees, and pharmacy/Optum contracts, with strong repeat revenue from long-term employer and government contracts plus recurring Optum platform usage. Competitive moat derives from massive scale (serving ~50 million via UnitedHealthcare and 123+ million via Optum in 2025), proprietary data assets, integrated care delivery, and network effects that are extremely difficult for competitors to replicate at similar efficiency. **SECTION 3 — Financial Deep Dive** 📈 Key metrics (Q1 2026 reported April 21 2026; FY 2025 from Jan 27 2026 release; TTM derived from quarterly data): Revenue: $111.7 billion (Q1 2026, +2% YoY); FY 2025 $447.6 billion (+12% YoY). Net income: Implied from EPS; Q1 GAAP EPS $6.90. EPS (adjusted): $7.23 (Q1 2026, beat by ~66 cents). Margins: Medical care ratio pressured but stabilizing; operating margin recovering. Free cash flow: Strong at $8.9 billion in Q1 2026 (1.4x net income). YoY growth rates: Revenue +2% (Q1); FY 2025 revenue +12%. Balance sheet health: Debt-to-capital ratio 42.9% (March 31 2026); cash flow supportive of leverage targets. Cash flow quality: Operating cash flow consistently exceeds net income (1.4-1.5x ratio). Capital allocation: Focus on R&D/AI investments (~$1.5 billion planned 2026), debt reduction to ~40% target, dividends, and selective M&A while resuming buybacks in H2 2026. **SECTION 4 — Growth Analysis** 🚀 Total addressable market (TAM): U.S. healthcare spending projected to exceed $6 trillion by 2030 (CMS estimates via industry reports). Current market share: Leading position in Medicare Advantage and commercial insurance; Optum dominant in PBM and value-based care. Key growth drivers next 3-5 years: Optum expansion in AI-enabled care, pharmacy services, and data analytics; UnitedHealthcare focus on employer and government segments with pricing discipline. Management raised 2026 guidance post-Q1 beat, signaling more bullish outlook than prior consensus; growth increasingly organic through technology leverage and portfolio optimization rather than acquisition-dependent. **SECTION 5 — Valuation** 📊 DCF analysis: Base case assumes mid-single-digit revenue CAGR, expanding operating margins to 5.5%+, WACC ~9%, terminal growth 3% . Implied value supports $360 target. Comparable company analysis (peers as of April 2026): CI ~12-14x forward P/E; ELV, HUM, CNC at 10-13x; UNH trades at premium but justified by scale. Historical valuation range (5-year): Forward P/E 18-25x. Bull target $420 (accelerated Optum AI gains); Base $360; Bear $280 (prolonged cost pressures). Current price ~$280-300 offers 20-30% upside to base target. **SECTION 6 — Risk Analysis** ⚠️ 1. Medical cost trend escalation (high probability/medium impact): Triggered by utilization spikes; watch quarterly medical loss ratio updates. 2. Regulatory changes in Medicare Advantage (medium-high): Reimbursement cuts or policy shifts; monitor CMS announcements. 3. Optum contract losses or margin compression (medium): Strategic exits noted; track segment earnings. 4. Cyber or operational disruptions (medium): Legacy from 2024-2025 events; monitor investment disclosures. 5. Macro healthcare spending slowdown (low-medium): Economic factors; watch employment data. Short interest low; insider activity shows typical patterns with no major red flags. No new accounting quality flags noted in latest filings. **SECTION 7 — Catalyst Calendar** 📅 Next earnings date: Already reported Q1 on April 21 2026 (conference call today at 8:00 AM ET). Upcoming events: Optum AI and technology updates throughout 2026; potential Medicare bid outcomes. Macro events: Federal budget/health policy decisions impacting reimbursement. 12-month timeline: Q2 earnings July 2026, continued membership adjustments, and leverage reduction milestones. **SECTION 8 — Technical Analysis** 📈 Primary Chart: Daily timeframe, 1-year view shows UNH consolidating in the $270-300 zone after 2025-2026 volatility, with today’s post-earnings reaction pushing toward recent highs. Price action recently crossed above the 50-day moving average while holding above key support; RSI (14) moving out of oversold territory with bullish MACD crossover and expanding volume. Major support zone $260-270, resistance $310-320. Visible setup: Potential inverse head-and-shoulders base with higher lows since February. Technical implication: Bullish bias confirmed by earnings catalyst with room for near-term continuation if volume sustains. **SECTION 9 — The Verdict** 🏆 Bull case ($420 target, 30 percent probability): Faster-than-expected margin recovery and Optum AI acceleration drive re-rating. Base case ($360 target, 50 percent probability): Steady execution on guidance with controlled medical costs. Bear case ($280 target, 20 percent probability): Persistent cost pressures or regulatory headwinds cap upside. Expected value calculation: Probability-weighted price target = $366. Final recommendation: Buy with High conviction. The 30-second elevator pitch: UnitedHealth just proved it can deliver despite industry challenges — with a Q1 beat, raised guidance, and unmatched scale across insurance and services, the stock offers attractive risk/reward as healthcare spending grows and margins normalize. **Sources** UnitedHealth Group press release April 21 2026 (Q1 2026 results); company FY 2025 results Jan 27 2026; Reuters/Seeking Alpha/Zacks earnings coverage April 21 2026; Yahoo Finance/TradingView charts and data as of April 21 2026; CMS healthcare spending projections. What are your thoughts on UNH? Drop them below 👇 #UNH #UnitedHealth #HealthcareStocks #Q1Earnings #EarningsBeat #Optum #MedicareAdvantage #StockMarket #HealthcareTurnaround #BuyTheDip
NYSE:UNHLong
by DCAlpha
UNH Earning Signal 2026-04-21Katy AI forecasts a sharp bearish reversal to $321.52 post-earnings, capitalizing on extreme overbought RSI (92.3) and low IV percentile despite recent Q1 beats raising the bar too high. Signal 🔴 BEARISH Alpha Score 72 (Quant Synthesis) # ⚡ QS V4 ELITE UNH (EARNINGS) * * | -------|:---------------| CORE THESIS Katy AI forecasts a sharp bearish reversal to $321.52 post-earnings, capitalizing on extreme overbought RSI (92.3) and low IV percentile despite recent Q1 beats raising the bar too high. ### ⬢ KATY AI EARNINGS VECTOR *Bias Bearish | Probability: 65% | Projected Move: -6.7% Tactical Observation Katy AI predicts bearish with 65% confidence, supported by overbought RSI (92.3) and put-heavy options flow (3 unusual puts, Put OI 32,773 vs. Call OI 48,113 despite 0.68 PCR), making a Bear Put Spread optimal to capture the projected downside while defining risk. STRATEGY BEAR PUT SPREAD | ALPHA EXPECTATION| | RISK GRADE 🚨 EXTREME (Binary Event) THESIS ERROR Earnings beat exceeding Katy AI projection with stock holding above $340 (upside surprise + IV crush) EXIT PROTOCOL Exit 100% at market open post-announcement to capture IV Crush or directional move. Risk Grade 🚨 EXTREME (Binary Event)
NYSE:UNHShort
by quantsignals_alpha
United Health - Starting a parabolic bullrun!🏅United Health ( NYSE:UNH ) is about to blow up: 🔎Analysis summary: United Health has been dropping about -60% over the past couple of months. But looking at long term history, this is just a very repetitive behavior. And considering that United Health is now at a three decade support trendline, it is the perfect time to start the next bullrun. 📝Levels to watch: $250 SwingTraderPhil SwingTrading.Simplified. | Investing.Simplified. | #LONGTERMVISION
NYSE:UNHLong
by TheTraderPhil
29
United Health - Losing $60bln in one day!📢United Health ( NYSE:UNH ) still overall remains bullish: 🔎Analysis summary: Just within a couple of hours, United Health wiped out $60bln. And despite this massive -20% drop, United Health is approaching a major confluence of support. After we see bullish confirmation, a rejection higher is very likely to follow in the future. 📝Levels to watch: $250 SwingTraderPhil SwingTrading.Simplified. | Investing.Simplified. | #LONGTERMVISION
NYSE:UNHLong
by TheTraderPhil
26
UNH: adding into fear after a completed ABC correctionThesis NYSE:UNH has completed its corrective ABC structure and is stabilizing within Wave 2, offering long-term accumulation opportunities in a proven cash-flow compounder. Context - Daily and weekly timeframes - Deep corrective phase already completed - Long-term uptrend remains intact on the weekly chart - Dividend-paying, high free-cash-flow defensive name What I see - Yesterday’s selloff was headline-driven, not structural - Price is holding inside the Wave 2 retracement zone - Volatility is shaking out weak hands, not breaking structure - This behavior is typical at the end of corrective phases - I added to my long-term position yesterday, bringing my average into the $270s What matters now - The priority is stabilization and base-building - A reclaim of the 50-day MA improves short-term structure - Reclaiming the 200-day MA confirms the next impulsive leg - Gap-filling narratives are noise, not a strategy Buy / Accumulation zone - Accumulation remains valid inside the current Wave 2 range - I have no issue adding again once price stabilizes - Risk is defined against the recent correction lows Targets - First major structural reference: 200-week MA near $460 - Wave 3 target remains the 1.618 Fib extension around $540 - Dividend yield (~2.6%) pays while waiting Execution note - This game isn’t for everyone — pressure exposes conviction - I added at $250 and $240 when sentiment was darkest - Buffett added at higher prices, yet fear returned instantly - NYSE:UNH is my current safe-haven: strong FCF, cash-rich, defensive This is a 3–5 year hold for me, not a short-term trade
NYSE:UNHLong
by maratteo
1